Showing results (391-400 of 420) with videos related to

Sort By:
Pageof 42
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid MalignanciesAparna Hegde, Priyamvada Jayaprakash, Coline A Couillault, et al.
JCO Oncology Practice|October 7, 2024
Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of PracticeNazli Dizman, Ziad Bakouny, Tarek Haykal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2017
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced CancersTakeo Fujii, Afsaneh Barzi, Andrea Sartore-Bianchi, et al.
Nature Medicine|April 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trialVivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
JCO Precision Oncology|January 15, 2026
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyDaniel R Carrizosa, Michael Rothe, Pam K Mangat, et al.
JCO Oncology Practice|December 4, 2025
Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck ConsortiumAllen S Ho, Justin T Moyers, Shirin Attarian, et al.
Molecular Cancer Therapeutics|May 22, 2016
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemFilip Janku, Helen J Huang, Bart Claes, et al.
The Lancet. Oncology|November 28, 2021
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialPatrick Y Wen, Alexander Stein, Martin van den Bent, et al.
JCO Global Oncology|August 22, 2022
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent ConsiderationsChristian Caglevic, Christian Rolfo, Ignacio Gil-Bazo, et al.
Pageof 42